Time	Function			
08:30-09:30	Registration and Breakfast			
09:30-11:05	Plenary Session - Hall: Teddy A			
09:30-09:35	Opening Session: Welcome & Introductory Remarks			
	Karin Mayer Rubinstein, CEO & President, Israel Advanced Technology Industries			
09:35-09:40	Yaacov Michlin, Conference Chair, CEO, BioLight Life Sciences Ltd.			
09:40-09:45	Greetings by President Isaac Herzog, President of Israel			
09:45-09:50	Stephanie L. Hallett, Deputy Chief of Mission at the U.S. Embassy in Jerusalem			
09:50-10:10	Hadassah Medical Organization: Designing the Future in Bio-Medicine and Innovation			
	Yoram G. Weiss, MD, MBA, FCCM, Director General, Hadassah Medical Organization, Associate Professor in Anesthesiology and			
	Critical Care Medicine, Hadassah Hebrew University School of Medicine			
10:10-10:35	Technology Impact on Patients and Healthcare Systems – Pros and Cons			
	Ran Balicer, MD, PhD, MPH, Deputy-DG, Chief Innovation Officer, Clalit Health Services, Israel, Founding Director, Clalit Research			
	Institute and Noa Heymann , Deputy Director of the Budget Department, Ministry of Finance			
10:35-10:50	Global Market Overview			
	Oded Spindel, Ph.D., MBA, Senior Vice President, Investment Banking, H.C. Wainwright & Co., LLC			
10:50-11:05	Dror Bin, CEO, Israel Innovation Authority			
11:05-11:30	Coffee Break			
11:30-13:00	Plenary Session			
11:30-11:45	Stepping Up Innovation to Drive Teva's Pivot to Growth			
	Eric A. Hughes, MD, PhD, Executive Vice President, Global Research & Development and Chief Medical Officer, Teva			
	Pharmaceuticals			
11:45-12:05	Ferring Leadership in Innovation			
	Bipin Dalmia, Senior Vice President, Uro-Oncology Head, Ferring Pharmaceuticals			
	Daphna Frenkiel-Krispin, PhD, MBA, Chief of Staff, Strategy and Realization Office Uro-Oncology Franchise, Ferring Pharmaceuticals			
12:05-12:20	Harnessing The Power of Patient Communities: Rare Disease and Israel's Potential			
	Alistair Grenfell, President Europe, Middle East, Africa and South Asia & Global Head of Public Health, IQVIA			



12:20-12:35	Next-Gen Skin Health: Merging AI, Wearables, and Data Analytics in Digital Dermatology Alexander Zink, MD, MPH, PhD, Consultant Physician at Department of Dermatology and Allergy, Technical University of Munich				
12:35-13:00	Panel: Redefining Hospitals: An Era of Digitization and Al-powered Healthcare Prof. Dr. Dr. h.c. mult. Jens Scholz, MBA, CEO of University Hospital Schleswig-Holstein (UKSH), Kiel and Lübeck, Germany Prof. Ronni Gamzu, CEO, Tel Aviv Sourasky Medical Center – Ichilov Liat Nadai Arad, Chief Transformation Officer & Head of I-Medata Al Center, Tel Aviv Sourasky Medical Center – Ichilov				
13:00-14:00	Lunch & Short Company Presentations: Salignostics, Betalin, Senseera, Itay&Beyond				
14:00-18:00	Parallel Tracks				
	Advancing Applied Research for Industry Excellence Beyond Today - Bench to Company Hot Trends By the Israel Tech Transfer Network (ITTN) Hall: Oren 3 14:00-18:00 14:00-15:45- PRESENTATIONS 16:00-17:00- WORKSHOP I 17:00-18:00- WORKSHOP II	Innovation, Health Data & Government What Do They Have in Common? Led by the Israel Innovation Authority Hall: Teddy B 14:00-18:00 14:00-15:00 – PRESENTATIONS 15:00-18:00 – MEETINGS WITH HEALTH ORGANIZATIONS Open to all MIXiii attendees	New Era of Hope: Shaping the Future of Rare Disease Therapeutics Hall: Oren 4 14:00-16:00 14:00-16:00 - PRESENTATIONS 14:00-14:05 Opening Remarks by Session Chair: Prof. Roni P. Dodiuk-Gad, MD, Faculties of Medicine, Technion - Institute of Technology, Israel & University of Toronto, Canada. Emek Medical Center, Israel		
	Beyond Today - Bench to Company Hot Trends Engaging talks by leading academic researchers and industry leaders. This session shall give the stage to scientists and physicians, whose research led to the establishment of	14:00-14:10 Ministry of Health, National Digital Agency & Israel Innovation Authority provides startups much needed beta sites and access to relevant data bases to test their innovations through engagement with relevant health organizations.	14:05-14:15 Accelerating Innovation: A Global Industry View of Next-Generation Therapies Alistair Grenfell, President Europe, Middle East, Africa and South Asia, IQVIA 14:15-14:30 Prader-Willi Syndrome, A		





International conservations and the state of		Devent / Duefeesienel Devention
biomedical companies and the industry		Parent/Professional Perspective on a Rare
representatives sharing their path.	Yael Hay Knobel, Senior Director	Disease Therapy
14:00-14:12	Technological Infrastructure Division,	Noam Josephy, MD, Vice President &
Opening Remarks by Session Chairs:	Israel Innovation Authority	General Manager, Innovation & AI,
<i>Dr. Tamar Raz,</i> CEO, Hadasit Health	Eyal Shaltieli, Digital Health Division,	Abiomed, J&J MedTech
Innovations and Co-Chair of ITTN &	Ministry of Health	
Keren Primor Cohen, CEO, Ramot at Tel	Yehuda Reuven, National Digital Agency	14:30-14:40
Aviv University and Co-Chair of ITTN		Rare Diseases in Israel 2024
	14:10-14:18	Dana Gelbaum, Co-Founder and Manager,
14:12-14:32	Renana Ofan, CEO, Sharre Zedek Scientific	Nedirot by 8400
Keynote: Making Real World Impact	(Madit)	,
with Advanced Technology and	Shmulik Shapiro, EVP Business	14:40-14:50
Innovative Connectivity	Development & Strategy, RSIP Vision	Harnessing the Power of Mitochondria to
Jonny Caplan, CEO & Co-Founder Tech		Treat Rare Disease
Talk Media Impossible Media		Noa Sher , PhD, Chief Scientist at Minovia
Tank Wedia Impossiole Wedia		Therapeutic
14:32-14:44	14:18-14:26	14:50-15:05
Dio Tree's Story: How an	Noa Bischitz, VP Business Development,	The Focus on Rare Diseases – The Big
Antidepressant Technology Got	Patho-Lab, Assuta Medical Centers	Pharma Approach
Commercialized as an Ovarian Cancer	Yair Heller, Chief Operations Officer, IBEX	Gianluca Pirozzi, MD, PhD, SVP,
First-In-Class Drug	run mener, chief Operations officer, IBEX	Development, Regulatory & Safety for
Prof. Bernard Lerer , Founder, Hadassah	14:26-14:34	Alexion, AstraZeneca Rare Disease
		Alexion, Astrazeneca kare disease
Medical Center; Prof. Osnat Ashur-	Michal Gordon, PhD, Director of Clinical	15:05-15:15
Fulsion Formulan CCO Main Hannital	Data Dasa and at Canalia Hamital	13.03 13.13
Fabian, Founder & CSO, Meir Hospital,	Data Research at Soroka Hospital	Preventing Skin Toxicities Induced by EGFR
Fabian, Founder & CSO, Meir Hospital, Dr. Sarit Batsir, CEO, Dio Tree	Alina Molchadsky, PhD, Head of Product,	
Dr. Sarit Batsir, CEO, Dio Tree		Preventing Skin Toxicities Induced by EGFR
Dr. Sarit Batsir, CEO, Dio Tree 14:44-14:56	Alina Molchadsky, PhD, Head of Product,	Preventing Skin Toxicities Induced by EGFR Inhibitors by Topically Blocking Drug-
Dr. Sarit Batsir, CEO, Dio Tree 14:44-14:56 IdentifAl Genetics: Early and Risk-Free	Alina Molchadsky, PhD, Head of Product, Renewal 14:34-14:42	Preventing Skin Toxicities Induced by EGFR Inhibitors by Topically Blocking Drug-Receptor Interaction
Dr. Sarit Batsir, CEO, Dio Tree 14:44-14:56 IdentifAl Genetics: Early and Risk-Free Prenatal Screening for All Syndromes	Alina Molchadsky, PhD, Head of Product, Renewal 14:34-14:42 Dr. Nofar Mor, Head of the RNA Therapy Program, SCRC, Sheha Medical Center	Preventing Skin Toxicities Induced by EGFR Inhibitors by Topically Blocking Drug- Receptor Interaction Dr. Sharon Merims, Head Dermato-
Dr. Sarit Batsir, CEO, Dio Tree 14:44-14:56 IdentifAl Genetics: Early and Risk-Free Prenatal Screening for All Syndromes Prof. Noam Shomron, Tel Aviv University	Alina Molchadsky, PhD, Head of Product, Renewal 14:34-14:42 Dr. Nofar Mor, Head of the RNA Therapy Program, SCRC, Sheba Medical Center	Preventing Skin Toxicities Induced by EGFR Inhibitors by Topically Blocking Drug- Receptor Interaction Dr. Sharon Merims, Head Dermato- Oncology Clinic, Center for Melanoma and Cancer Immunotherapy Sharett Institute of
Dr. Sarit Batsir, CEO, Dio Tree 14:44-14:56 IdentifAl Genetics: Early and Risk-Free Prenatal Screening for All Syndromes	Alina Molchadsky, PhD, Head of Product, Renewal 14:34-14:42 Dr. Nofar Mor, Head of the RNA Therapy Program, SCRC, Sheha Medical Center	Preventing Skin Toxicities Induced by EGFR Inhibitors by Topically Blocking Drug- Receptor Interaction Dr. Sharon Merims, Head Dermato- Oncology Clinic, Center for Melanoma and



14:56-15:18

UNI Therapeutics: An AI Technology Utilizing the Power of Evolution to Finding New Drugs

Prof. Yuval Tabach, Hebrew University. **Sagi Gidali,** Co-Founder Rafa's Moonshot

15:18-15:30

Medical Sonosphere: Introducing Novel Ultrasound Technology for Merging Physiological Data and Mapping the Surface of the Patient's Body Dr. Chen Speter, Sheba Medical Center, Director; Ilan landesman, CEO, Medical Sonosphere

15:30-15:42

NanoGhost: A Delivery Platform
Harnessing the Power of Stem Cells to
Target Cancer and Neuro Inflammatory
Diseases

Prof. Marcelle Machluf, Technion - Israel Institute of Technology; **Yonatan Malca**, CEO, NanoGhost

Ariel Feiglin, CSO, Skip Therapeutics

14:42-14:50

Izhar Laufer, Director, Leumit Start *Yoram Hordan*, Co-Founder and COO/CTO, FeelBetter

14:50-15:00

Global Health Tech Innovations:
Unlocking Funding Collaborations
Tal Ben Avner, Director of Singapore
Fund, Israel Innovation Authority

15:00-17:40

Meetings with Health Organization
Open to all conference attendees

15:15-15:30

The Role of The ALS Community in Advancing The Cure / Treatment Efrat Carmi, CEO, IsrA.L.S & Avichai Kremer, Development Consultant, The ALS Association

15:30-15:45

A Rare Disease with A Higher Prevalence In The Ashkenazi Jewish Population - As An Opportunity To Develop Innovative Therapies?

Prof. Ari Zimran, MD, Founder & Former Head of the Gaucher Unit at Shaare Zedek Medical Center

15:45-15:50

Closing Remarks

Professor Roni P. Dodiuk-Gad, MD

Faculties of Medicine, Technion - Institute of Technology, Israel & University of Toronto, Canada. Emek Medical Center, Israel.

15:45-16:00

Coffee Break





Parallel Tracks

Advancing Applied Research for Industry Excellence Beyond Today - Bench to Company Hot Trends

By the Israel Tech Transfer Network (ITTN)

Hall: Oren 3 14:00-18:00

16:00-17:00

Professional Workshop 1: Patent

Management and Intellectual Property



by Experts

Led by Dr. Gal Ehrlich, Patent Attorney, Founder and General Manager, Ehrlich & Fenster of The Ehrlich Group (EG)

Dr. Hadassa Waterman, Head of Biotech Department Ehrlich Group **Adv. Roy Melzer**, Head of Computing Technologies Department Ehrlich Group **Maier Fenster**, Head of Medical Devices Department Ehrlich Group

Innovation, Health Data & Government
What Do They Have in Common?

Led by the Israel Innovation
Authority

Continues

Hall: Teddy B
15:00-18:00
MEETINGS WITH HEALTH ORGANIZATIONS
Open to all MIXiii attendees

Innovation in Translating Science to Clinic in CNS Disorders

&

Student Poster Competition Awards
Led by Teva Pharmaceuticals

Hall: Oren 4 16:00-18:00

16:00-16:10

Introductory Remarks by Session Chair:

Dr. Eran Harary, SVP, Global Head of Early
Clinical Development, Global R&D, Teva
Pharmaceuticals

16:10-16:30

PTSD, Detection Prevention and Therapy: Gaps and Innovations' Opportunities Prof. Arieh Y. Shalev, Emeritus Professor of Psychiatry, Hadassah and the Hebrew University School of Medicine, Jerusalem

16:30-16:50

Exploring The Effectiveness of Novel Treatment Targeting Myelination Deficits on Improving Cognitive Deficits in Williams Syndrome

Prof. Dr. Doron Gothelf, Director of the Child @ Adolescent Psychiatric Division, Sheba Medical Center







Beneficial Considerations for Managing 16:50-17:10 **IP Portfolios Under Financial Crisis: How Transplanted Brain Organoids Help** Some Common Dilemmas. **Us Discover New Therapies for Neuropsychiatric Disorders** > IP protection is costly to obtain and maintain, but, through monopoly, can Dr. Omer Revah, DVM PhD, Hebrew University, Koret School of Veterinary generate > prodigious value for the Medicine company. > Budget is, always and especially at these times, limited. 17:10-17:30 > Immediate question arises - what to **Breakthroughs in Cancer Therapeutics, Expanding the Boundaries of Biologics** spend your IP budget on? > In this panel we will discuss some Dr. Tehila Ben Moshe, CEO, Biond Biologics common situations where tradeoffs can be considered with their associated pros and cons. 17:00-18:00 17:30-18:00 Hall: Teddy B **Student Poster Competition Awards Professional Workshop 2: Understanding Technology Contracts Presentations** Hosted by: Dr. Dana Bar-On, Senior and Licensing 15:00-18:00 Director, Head of Global Academic MEETINGS WITH HEALTH ORGANIZATIONS PEARL COHEN Open to all MIXiii attendees Collaborations, Teva Pharmaceuticals Led by Adv. Yael Baratz, Senior Partner, Chair of the IL Corporate & Licensing Group, Pearl Cohen Zedek Latzer Baratz **Continues** Noam Waldoks, General Counsel, aMoon Liron Zusman-Azulay, General Counsel, Ramot at Tel Aviv University Ltd. Lani Questembert, Deputy General Counsel, Yissum Ltd.



Modi Teicher, Chief Business Officer, FutuRx

Dissecting a TS: In-depth conversation on the business aspects of technology contracts and licensing

In this workshop we will discuss various components of the business aspects of technology contracts and licensing agreements and will share best practices and insights.

The main topics to be discussed are:

- The definition of "Licensed Product"
- The royalty term
- Field restrictions



